Latest Headlines

Latest Headlines

AstraZeneca adds Lilly to its stable of immuno-oncology collaborators

AstraZeneca believes the brightest future for its top oncology prospect will come through collaboration, recruiting Eli Lilly to its growing ranks of partners with eyes on kicking off a combination cancer trial.

Untried drug candidates can find a home at Japan's newly minted AMED

The Japan Agency for Medical Research and Development, created less than two months ago in the model of the U.S. NIH, is now ready to receive up to 200,000 substance samples from more than 10 drugmakers. In exchange for providing the substances free of charge, AMED said it would work with universities and other researchers to test a substance's use in treating various diseases and ailments, such as cancer and infection.

Medtronic's Ishrak eyes China 'value products' market

Medtronic, known mostly for its high-priced medical devices, is looking for some deals in China as it chases low-price customers for its line of "value products."

Mitsubishi Chemical unit in stem call play with Clio

Mitsubishi Chemical Holdings unit Life Science Institute has bought multilineage-differentiating stress-enduring (Muse) stem cell firm Clio for more than 1 billion yen ($8 million), according to a press release. Life Sciences in a Japanese language release on May 14 said Clio will become a wholly-owned subsidiary.

BioClinica partners up for risk-based management

BioClinica has inked a deal with consulting firm Kinapse to help spread the adoption of its risk-based monitoring service, a targeted approach to keeping tabs on trials.

Serum Institute, Cipla partner to market flu vaccine in India

Serum Institute of India and compatriot Cipla have inked a pact to market a flu vaccine.

J&J sets up innovation hub inside Karolinska Institutet

Johnson & Johnson has established an outpost within Karolinska Institutet. The arrangement sees J&J set an innovation hub at the Swedish medical university, from which it will keep tabs on academic research breakthroughs and support the advance of such ideas into life science startups.

Singapore clinical hub to work with Visterra on dengue candidate

Singapore's research agency and Duke-National University of Singapore have signed an agreement to collaborate with U.S. biotech Visterra on getting a promising treatment against dengue fever to the clinical-trial stage.

Biocartis to develop respiratory panel tests with Fast-track diagnostics

Fast-track diagnostics will develop assays for use on Biocartis' Idylla testing platform, which searches for multiple pathogens following a single test, or what's known as syndromic multiplex testing.

Bluebird widens its CAR-T ambitions with a $130M Five Prime deal

Bluebird bio, already making headlines with its promising gene therapy, is expanding its efforts in immuno-oncology, pairing up with Five Prime Therapeutics to develop cell therapies for cancer.